/
Oncology
Soft Tissue Sarcoma
74
Pipeline Programs↗
88
Active Trials↗
58
Companies Involved↗
Soft Tissue Sarcoma is a moderately active landscape with 74 programs across 58 companies. The most active players are AstraZeneca, HRYZ Biotech Co.. 18 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 110
Phase 238
Phase 318
Approved
No programs
Analysis
Modality Breakdown
73%
Small molecule
51 of 70 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 70 classified programs, each share of the total. Modality classified for 97% of 74 pipeline programs.
Analysis
Trial Status
348
clinical trials
Completed161 · 46%
Recruiting52 · 15%
Unknown status48 · 14%
Terminated35 · 10%
Active, not recruiting24 · 7%
Not yet recruiting12 · 3%
Other16 · 5%
Clinical Trials
Trial Activity
348 trials
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma
Recruiting·—·Preclinical·NCT06797999·270 enrolled
Page 1 of 24
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)